Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.

作者: Armando López-Guillermo , Fernando Cabanillas , Timothy I. McDonnell , Peter McLaughlin , Terry Smith

DOI: 10.1182/BLOOD.V93.9.3081

关键词:

摘要: The t(14;18) translocation, which involves the bcl-2 oncogene, occurs in follicular lymphomas (FL) at two common sites: major breakpoint region ( MBR ) and minor cluster mcr ). biological clinical significance of these breakpoints is unknown. site was determined 247 previously untreated patients (49% men; median age 52 years) with indolent FL (155 grade I, 83 II, 8 III) to correlate it pretreatment characteristics, response, outcome. by a polymerase chain reaction method peripheral blood (all cases), bone marrows (149 fresh lymph node biopsy specimens (68 cases). occurred 175 cases (71%) 27 (11%). In 45 (18%), no detected (germline). No significant relationship found between rearrangements expression BLC-2 BAX proteins. Patients’ germline for tended present more frequently stage IV disease higher β2-microglobulin (β2M) levels, whereas -rearranged presented early normal β2M. complete response rate significantly lower than that patients. An estimated 3-year failure-free survival (FFS) , MBR, 95%, 76%, 57%, respectively P  < .001). independent serum β2M lactate dehydrogenase its correlation FFS. conclusion, rearrangement an important prognostic factor FL, useful identify who may require different treatment.

参考文章(45)
J Limpens, R Stad, C Vos, C de Vlaam, D de Jong, GJ van Ommen, E Schuuring, PM Kluin, Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals Blood. ,vol. 85, pp. 2528- 2536 ,(1995) , 10.1182/BLOOD.V85.9.2528.BLOODJOURNAL8592528
T Yano, ES Jaffe, DL Longo, M Raffeld, MYC rearrangements in histologically progressed follicular lymphomas Blood. ,vol. 80, pp. 758- 767 ,(1992) , 10.1182/BLOOD.V80.3.758.758
H Tilly, A Rossi, A Stamatoullas, B Lenormand, C Bigorgne, A Kunlin, M Monconduit, C Bastard, Prognostic value of chromosomal abnormalities in follicular lymphoma Blood. ,vol. 84, pp. 1043- 1049 ,(1994) , 10.1182/BLOOD.V84.4.1043.1043
Christian A Sander, Takahiro Yano, Helen M Clark, Cynthia Harris, Dan L Longo, Elaine S Jaffe, Mark Raffeld, None, p53 mutation is associated with progression in follicular lymphomas Blood. ,vol. 82, pp. 1994- 2004 ,(1993) , 10.1182/BLOOD.V82.7.1994.1994
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
ME Hill, KA MacLennan, DC Cunningham, B Vaughan Hudson, M Burke, P Clarke, F Di Stefano, L Anderson, G Vaughan Hudson, D Mason, P Selby, DC Linch, Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood. ,vol. 88, pp. 1046- 1051 ,(1996) , 10.1182/BLOOD.V88.3.1046.1046
N L Berinstein, M D Reis, B Y Ngan, C A Sawka, H H Jamal, B Kuzniar, Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. Journal of Clinical Oncology. ,vol. 11, pp. 1344- 1352 ,(1993) , 10.1200/JCO.1993.11.7.1344
P McLaughlin, F B Hagemeister, J E Romaguera, A H Sarris, O Pate, A Younes, F Swan, M Keating, F Cabanillas, Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. Journal of Clinical Oncology. ,vol. 14, pp. 1262- 1268 ,(1996) , 10.1200/JCO.1996.14.4.1262
Jorge J. Yunis, Mary G. Mayer, Mark A. Arnesen, Dorothee P. Aeppli, Martin M. Oken, Glauco Frizzera, bcl-2 and Other Genomic Alterations in the Prognosis of Large-Cell Lymphoma The New England Journal of Medicine. ,vol. 320, pp. 1047- 1054 ,(1989) , 10.1056/NEJM198904203201605